Jinyao Pharmaceutical: Receives Approval Notice for Marketing Application of Diphenhydramine Hydrochloride API
Jinyao Pharmaceutical announced that the company has received the "Chemical API Marketing Application Approval Notice" for diphenhydramine hydrochloride issued upon approval by the National Medical Products Administration. The API meets drug registration requirements and has been approved for registration and may be sold in the domestic market. Its current status on the CDE raw and auxiliary materials registration information platform is "A". Diphenhydramine hydrochloride is a first-generation antihistamine, mainly used to treat allergic dermatitis, urticaria, allergic rhinitis, etc. To date, the company's cumulative R&D investment in this project is approximately RMB 2.11 million. There is uncertainty regarding the commencement of production and subsequent market sales of this drug. Investors are advised to be aware of investment risks.
Latest
4 m ago

